| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneurop... |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropa... |
| 12 Jun 2026 |
8-K: Other Events
Advancing a leading autoimmune-focused company June 2026 Exhibit 99.1 |
| 22 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 21, 2026, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”) to consider and vote on the three proposals set forth below, each of which is described in greater detail in the Company’s Definitive Proxy State... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A |
| 26 Mar 2026 |
8-K: Other Events
Advancing a leading autoimmune-focused company March 2026 Exhibit 99.1 |
| 12 Mar 2026 |
8-K: Entry into a Material Definitive Agreement
Introductory. Dianthus Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 7,313,582 shares of its common stock, ... |
| 09 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS, INCLUDING GO DECISION FOR PHASE 3 CAPTIVATE CIDP TRIAL, |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Advancing a leading autoimmune-focused company January 2026 Exhibit 99.1 |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy measures at Week 13 in Phase 2 MaGi... |
| 03 Nov 2025 |
8-K: Other Events
Forward-looking statements Certain statements in this presentation, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the sa... |
| 16 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
Dianthus Therapeutics Licensing of DNTH212 (BDCA2 and BAFF/APRIL) from Leads Biolabs October 16, 2025 Exhibit 99.1 |
| 11 Sep 2025 |
8-K: Entry into a Material Definitive Agreement
Introductory. Dianthus Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 6,487,879 shares of its common stock, ... |
| 08 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
DIANTHUS THERAPEUTICS ANNOUNCES POSITIVE DATA FOR CLASEPRUBART (DNTH103) FROM THE PHASE 2 MAGIC TRIAL IN GENERALIZED MYASTHENIA GRAVIS, SUPPORTING ITS POTENTIAL BEST-IN-CLASS PROFILE |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in September 2025; the first of three catalysts for the claseprubart neuromuscular franchise by YE’26 |
| 22 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
On May 22 2025, Leon O. Moulder, Jr., a member of the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective immediately. Mr. Moulder’s resignatio... |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG)s |
| 11 Mar 2025 |
8-K: Results of Operations and Financial Condition
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25 |
| 05 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 4, 2025, Tomas Kiselak, a member of the Board of Directors (the “Board) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective as of the close of business on March 4, 202... |
| 12 Dec 2024 |
8-K: Other Events
FORWARD-LOOKING STATEMENTS Certain statements in this presentation (“Presentation”), other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for p... |
Loading...